Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Prothena Corporation plc

Healthcare US PRTA

9.25USD
0.33(3.70%)

Last update at 2026-06-04T20:00:00Z

Day Range

9.039.45
LowHigh

52 Week Range

19.6577.13
LowHigh

Fundamentals

  • Previous Close 8.92
  • Market Cap1072.75M
  • Volume504475
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-215.29699M
  • Revenue TTM89.25M
  • Revenue Per Share TTM1.67
  • Gross Profit TTM -81.65700M
  • Diluted EPS TTM-3.21

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -160.48000M -125.60500M 71.92M -111.42700M -77.29800M
Minority interest - - - - -
Net income -147.02800M -116.94900M 66.97M -111.14400M -77.67700M
Selling general administrative 61.84M 49.90M 46.32M 38.70M 35.74M
Selling and marketing expenses - - - - -
Gross profit 82.96M 53.91M 200.58M 0.85M -50.02200M
Reconciled depreciation 0.93M 0.74M 6.80M 6.98M 6.82M
Ebit -191.03600M -131.55700M 71.97M -112.73400M -85.69700M
Ebitda -190.10800M -130.81300M 78.78M -105.75700M -85.81900M
Depreciation and amortization 0.93M 0.74M 6.80M 6.98M -0.12200M
Non operating income net other - - -0.09600M -0.06200M 0.20M
Operating income -191.03600M -131.55700M 71.97M -112.73400M -85.69700M
Other operating expenses 282.41M 185.46M 128.60M 113.59M 86.57M
Interest expense - 6.70M 6.75M 8.28M 8.20M
Tax provision -13.45200M -8.65600M 4.95M -0.28300M 0.38M
Interest income 31.01M 6.35M 0.04M 1.37M 8.20M
Net interest income 31.01M 6.35M 0.04M 1.37M 8.20M
Extraordinary items - - - - -
Non recurring - - - - -0.06100M
Other items - - - - -
Income tax expense -13.45200M -8.65600M 4.95M -0.28300M 0.38M
Total revenue 91.37M 53.91M 200.58M 0.85M 0.81M
Total operating expenses 282.41M 185.46M 128.60M 113.59M 86.57M
Cost of revenue 8.41M 6.74M 82.28M 74.88M 50.84M
Total other income expense net 30.56M 5.95M -0.05400M 1.31M 8.40M
Discontinued operations - - - - -
Net income from continuing ops -147.02800M -116.94900M 66.97M -111.14400M -77.67700M
Net income applicable to common shares - -116.94900M 66.97M -111.14400M -77.67700M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 696.38M 758.03M 609.37M 332.98M 419.27M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 19.10M 8.69M 5.71M 2.54M 2.65M
Total liab 135.02M 135.99M 143.32M 148.97M 146.35M
Total stockholder equity 561.37M 622.04M 466.04M 184.01M 272.92M
Deferred long term liab - - 102.93M 110.24M 110.24M
Other current liab -37.01900M 22.96M 16.16M 11.29M 6.79M
Common stock 0.54M 0.52M 0.47M 0.40M 0.40M
Capital stock 0.54M 0.52M 0.47M 0.40M 0.40M
Retained earnings -980.03100M -833.00300M -716.05400M -783.02900M -671.88500M
Other liab - 85.85M 103.49M 110.80M 110.80M
Good will - - - - -
Other assets - 30.93M 10.42M 31.14M 13.74M
Cash 620.18M 710.41M 579.09M 295.38M 375.72M
Cash and equivalents - - - - -
Total current liabilities 56.89M 50.15M 33.45M 25.85M 17.71M
Current deferred revenue 67.41M 11.44M 7.66M 4.93M 4.58M
Net debt -608.34700M -703.93300M -566.76800M -277.54200M -352.78400M
Short term debt 1.11M 6.47M 5.94M 5.51M 5.10M
Short long term debt - - - - -
Short long term debt total 11.84M 6.47M 12.33M 17.84M 22.94M
Other stockholder equity 1540.86M 1454.52M 1181.63M 966.64M 944.41M
Property plant equipment - 8.01M 2.01M 2.55M 3.87M
Total current assets 639.28M 719.10M 584.81M 299.28M 378.38M
Long term investments - - - - -
Net tangible assets - 622.04M 466.04M 184.01M 272.92M
Short term investments - - - - -
Net receivables 5.16M 0.06M 0.01M 0.01M 0.07M
Long term debt - - - - -
Inventory -5.15900M -0.06200M - 1.35M -0.06800M
Accounts payable 25.39M 9.27M 3.69M 4.12M 1.24M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -8.00700M
Additional paid in capital - - - - -
Common stock total equity - - 0.47M 0.40M 0.40M
Preferred stock total equity - - - - -
Retained earnings total equity - - -716.05400M -783.02900M -671.88500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 40.24M 12.72M 3.35M 1.69M 3.79M
Deferred long term asset charges - - - - 9.96M
Non current assets total 57.10M 38.94M 24.56M 33.69M 40.89M
Capital lease obligations 11.84M 6.47M 12.33M 17.84M 22.94M
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -1.41200M -0.46400M -0.57500M -0.19600M -0.54700M
Change to liabilities - -1.99000M -0.14400M 7.73M -0.53900M
Total cashflows from investing activities - -0.46400M -0.57500M -0.19600M -0.54700M
Net borrowings - - - - -
Total cash from financing activities 45.10M 241.46M 190.33M 0.21M 0.23M
Change to operating activities - -16.81300M -10.27500M -4.30200M -4.37100M
Net income -147.02800M -116.94900M 66.97M -111.14400M -77.67700M
Change in cash -90.22400M 132.17M 282.36M -80.34300M -53.28800M
Begin period cash flow 710.41M 580.45M 298.08M 378.43M 431.71M
End period cash flow 620.18M 712.62M 580.45M 298.08M 378.43M
Total cash from operating activities -133.90600M -108.82100M 92.61M -80.36200M -52.96900M
Issuance of capital stock 232.78M 223.62M 174.79M 78.37M -
Depreciation 0.93M 0.74M 6.80M 6.98M 6.82M
Other cashflows from investing activities - - - - 0.00800M
Dividends paid - - - - -
Change to inventory -8.89600M - -10.27500M - -
Change to account receivables -5.15900M 0.08M 0.01M 0.05M 0.05M
Sale purchase of stock - - 93.59M 0.21M 0.23M
Other cashflows from financing activities 45.10M 17.84M 190.33M 0.21M 0.23M
Change to netincome - 20.19M 4.57M -1.68800M -1.24800M
Capital expenditures 2.81M 0.46M 0.57M 0.20M 0.56M
Change receivables - - 0.01M 0.05M -
Cash flows other operating - - 20.07M 23.18M 24.93M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 282.36M -80.34300M -53.28800M
Change in working capital -20.53000M -18.80300M -10.40400M 3.48M -4.44900M
Stock based compensation 40.91M 31.32M 24.66M 22.01M 23.59M
Other non cash items 7.50M 6.00M 38.74M 28.19M 51.35M
Free cash flow -136.71600M -109.28500M 92.03M -80.55800M -53.52400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PRTA
Prothena Corporation plc		 0.33 3.70% 9.25 - 64.10 13.08 2.13 6.43 -3.0917
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Prothena Corporation plc

77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60

Key Executives

Name Title Year Born
Dr. Gene G. Kinney Ph.D. Pres, CEO & Director 1969
Mr. Tran B. Nguyen M.B.A. CFO & Chief Strategy Officer 1974
Mr. Brandon S. Smith Chief Operating Officer 1975
Ms. Carol D. Karp Chief Regulatory Officer 1953
Dr. Hideki Garren M.D., Ph.D. Chief Medical Officer 1965
Ms. Karin L. Walker CPA, CPA Chief Accounting Officer & Controller 1963
Dr. Wagner M. Zago Chief Scientific Officer 1973
Ms. Jennifer Zibuda Director of Investor Relations & Communication NA
Mr. Michael J. Malecek Chief Legal Officer 1966
Ms. Yvonne M. Tchrakian Company Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions